Research on Sensitive Blood Test for Cancer Wins 2
Post# of 129
(Total Views: 209)
Posted On: 02/26/2021 4:55:04 PM
Research on Sensitive Blood Test for Cancer Wins 2021 Top-10 Award
The Clinical Research Forum recently awarded cancer biologists from Weill Cornell Medicine its Top-10 Clinical Research Achievement Award for their 2020 study that described a sensitive blood test for detecting a cancer relapse or the disease’s progression. The findings of the study were reported in “Nature Medicine.”
The group of researchers was led by associate professor of medicine, Dr. Dan Landau, who is also a member of the Sandra and Edward Meyer Cancer Center. The study’s first author was Dr. Asaf Zviran, a postdoctoral researcher in Landau’s laboratory.
The model developed in their study utilizes DNA whole-genome sequencing of a patient’s blood to monitor mutations that exist in the patient’s tumors. This platform for detecting cancer is run by machine learning algorithms and can identify thousands of different tumor-related mutations.
This particular feature makes the platform useful for use in circumstances where standard liquid biopsy methods fall short because of high fragmentation or low concentration of the DNA of tumors in a patient’s blood. The method’s goal is to allow doctors to keep an eye on a patient’s response to treatment and monitor the disease’s progression more keenly. This may also help boost the efficacy of the current treatments.
The award granted to these cancer biologists is one of 10 awarded yearly by the research forum for clinical translatable research that is not only highly innovative but also has the potential to offer patients major benefits. The winners of the 10 awards will present their award-wining studies on March 30, 2021, at the annual meeting of the Clinical Research Forum, which will be held online because of the ongoing coronavirus pandemic.
The organization, based in Washington, DC, is a strong champion for government funding of clinical research in the United States and various clinical research institutions interests as well.
Landau, who also happens to be a New York Genome Center member, stated that the team, as well as himself, were grateful for the award and especially pleased that the research forum had realized the potential the technology possessed, which could revolutionize cancer care. Landau and his group of researchers are working on advancing the platform, which they dubbed MRDetect. The lab has collaborated with Weill Cornell Medicine partners to increase the method’s sensitivity further and improve its machine learning approach. Additionally, they are testing the method’s ability to assist doctors in optimizing novel immunotherapy treatments for some cancers.
Still on the subject of modernizing health care, Brain Scientific Inc. (OTCQB: BRSF) is pursuing its mission of developing proprietary and innovative software and medical devices, which are intended to take brain diagnostics to the next level. To this end, two of the company’s devices have already attained FDA-approval.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
The Clinical Research Forum recently awarded cancer biologists from Weill Cornell Medicine its Top-10 Clinical Research Achievement Award for their 2020 study that described a sensitive blood test for detecting a cancer relapse or the disease’s progression. The findings of the study were reported in “Nature Medicine.”
The group of researchers was led by associate professor of medicine, Dr. Dan Landau, who is also a member of the Sandra and Edward Meyer Cancer Center. The study’s first author was Dr. Asaf Zviran, a postdoctoral researcher in Landau’s laboratory.
The model developed in their study utilizes DNA whole-genome sequencing of a patient’s blood to monitor mutations that exist in the patient’s tumors. This platform for detecting cancer is run by machine learning algorithms and can identify thousands of different tumor-related mutations.
This particular feature makes the platform useful for use in circumstances where standard liquid biopsy methods fall short because of high fragmentation or low concentration of the DNA of tumors in a patient’s blood. The method’s goal is to allow doctors to keep an eye on a patient’s response to treatment and monitor the disease’s progression more keenly. This may also help boost the efficacy of the current treatments.
The award granted to these cancer biologists is one of 10 awarded yearly by the research forum for clinical translatable research that is not only highly innovative but also has the potential to offer patients major benefits. The winners of the 10 awards will present their award-wining studies on March 30, 2021, at the annual meeting of the Clinical Research Forum, which will be held online because of the ongoing coronavirus pandemic.
The organization, based in Washington, DC, is a strong champion for government funding of clinical research in the United States and various clinical research institutions interests as well.
Landau, who also happens to be a New York Genome Center member, stated that the team, as well as himself, were grateful for the award and especially pleased that the research forum had realized the potential the technology possessed, which could revolutionize cancer care. Landau and his group of researchers are working on advancing the platform, which they dubbed MRDetect. The lab has collaborated with Weill Cornell Medicine partners to increase the method’s sensitivity further and improve its machine learning approach. Additionally, they are testing the method’s ability to assist doctors in optimizing novel immunotherapy treatments for some cancers.
Still on the subject of modernizing health care, Brain Scientific Inc. (OTCQB: BRSF) is pursuing its mission of developing proprietary and innovative software and medical devices, which are intended to take brain diagnostics to the next level. To this end, two of the company’s devices have already attained FDA-approval.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
(0)
(0)